









市場行情
/
股票
/
nasdaq-amrn
/

Amarin Corporation PLC

AMRN

13.785USD

+0.185+1.36%

交易中（美東）報價延遲15分鐘

286.70M總市值

虧損本益比TTM



Amarin Corporation PLC

13.785

+0.185+1.36%

概覽公司財務分析

概覽

公司

財務

分析

關於 Amarin Corporation PLC 公司

Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.

Amarin Corporation PLC簡介



公司代碼AMRN

公司名稱Amarin Corporation PLC

上市日期Apr 01, 1993

CEOBerg (Aaron D)

員工數量275

證券類型Depository Receipt

年結日Apr 01

公司地址WeWork One Central Plaza Dame Street

城市DUBLIN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家Ireland

郵編D02 K7K5

電話35316699020

網址https://amarincorp.com/

公司代碼AMRN

上市日期Apr 01, 1993

CEOBerg (Aaron D)

Amarin Corporation PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

Ms. Patrice Bonfiglio

Non-Executive Independent Director

Mr. Louis Sterling, III

Non-Executive Independent Director

Mr. Peter Fishman

Chief Financial Officer

Dr. Stephen B. (Steven) Ketchum, Ph.D.

President - Research and Development, Executive Vice President, Chief Scientific Officer

Mr. Aaron D. Berg

President, Chief Executive Officer, Director

Mr. Keith L. Horn

Non-Executive Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. David Keenan, Ph.D.

Chief Operating Officer, Executive Vice President

7.95K

Ms. Diane E. Sullivan

Non-Executive Independent Director

401.00

Mr. Oliver O'Connor

Non-Executive Independent Director

401.00

Dr. Paul Cohen, M.D.

Non-Executive Independent Director

401.00

Ms. Patrice Bonfiglio

Non-Executive Independent Director

Mr. Louis Sterling, III

Non-Executive Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

2.20%

Morgan Stanley & Co. LLC

1.21%

Eversept Partners, LP

0.80%

其他

87.04%

持股股東

佔比

Sarissa Capital Management, L.P.

5.98%

Kynam Capital Management LP

2.77%

Acadian Asset Management LLC

2.20%

Morgan Stanley & Co. LLC

1.21%

Eversept Partners, LP

0.80%

其他

87.04%

股東類型

持股股東

佔比

Hedge Fund

12.07%

Investment Advisor/Hedge Fund

2.95%

Investment Advisor

2.79%

Research Firm

1.93%

Individual Investor

0.99%

Pension Fund

0.35%

Family Office

0.24%

其他

78.69%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

291

4.18M

22.49%

+4.06K

2025Q3

314

4.20M

24.13%

+467.66K

2025Q2

330

3.80M

23.58%

+94.36K

2025Q1

338

3.76M

23.88%

-1.19M

2024Q4

355

3.75M

23.57%

+236.09K

2024Q3

360

3.51M

29.65%

-554.68K

2024Q2

386

4.06M

34.43%

-548.92K

2024Q1

399

4.62M

36.64%

-2.90M

2023Q4

416

4.89M

38.80%

+197.93K

2023Q3

435

4.67M

42.33%

-650.41K

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Sarissa Capital Management, L.P.

1.24M

6.01%

-4.00

-0.00%

Jun 30, 2025

Kynam Capital Management LP

576.11K

2.79%

-44.62K

-7.19%

Jun 30, 2025

Acadian Asset Management LLC

241.05K

1.17%

+51.47K

+27.15%

Jun 30, 2025

Morgan Stanley & Co. LLC

147.27K

0.71%

+31.23K

+26.91%

Jun 30, 2025

Eversept Partners, LP

167.28K

0.81%

-2.68K

-1.58%

Jun 30, 2025

Millennium Management LLC

45.24K

0.22%

+44.25K

+4470.10%

Jun 30, 2025

Citadel Advisors LLC

45.46K

0.22%

+45.46K

Jun 30, 2025

SCP Investment, LP

125.00K

0.6%

Jun 30, 2025

BNP Paribas Securities Corp. North America

75.94K

0.37%

+4.35K

+6.07%

Jun 30, 2025

Longitude (Cayman) Ltd

81.00K

0.39%

-37.50K

-31.65%

Dec 31, 2024

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ProShares Ultra Nasdaq Biotechnology

0.04%

Invesco Nasdaq Biotechnology ETF

0.03%

SPDR S&P International Small Cap ETF

0.02%

Global X Aging Population ETF

ActivePassive International Equity ETF

Invesco NASDAQ Future Gen 200 ETF

SPDR Portfolio Developed World ex-US ETF

ProShares Ultra Nasdaq Biotechnology

佔比0.04%

Invesco Nasdaq Biotechnology ETF

佔比0.03%

SPDR S&P International Small Cap ETF

佔比0.02%

Global X Aging Population ETF

佔比0%

ActivePassive International Equity ETF

佔比0%

Invesco NASDAQ Future Gen 200 ETF

佔比0%

SPDR Portfolio Developed World ex-US ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Mar 12, 2025

Merger

20→1

Mar 12, 2025

Merger

20→1

公告日期

類型

比率

Mar 12, 2025

Merger

20→1

Mar 12, 2025

Merger

20→1

常見問題

Amarin Corporation PLC的前五大股東是誰？



Amarin Corporation PLC的前五大股東如下：
Sarissa Capital Management, L.P.
持有股份：1.24M
佔總股份比例：6.01%。
Kynam Capital Management LP
持有股份：576.11K
佔總股份比例：2.79%。
Acadian Asset Management LLC
持有股份：241.05K
佔總股份比例：1.17%。
Morgan Stanley & Co. LLC
持有股份：147.27K
佔總股份比例：0.71%。
Eversept Partners, LP
持有股份：167.28K
佔總股份比例：0.81%。